Ogivri® (trastuzumab-dkst)
for Gastric Cancer Stomach Cancer

Ogivri (trastuzumab-dkst) is a biosimilar to Herceptin used to treat HER2-positive breast and stomach cancer, sometimes in combination with other treatments. It may be used when the cancer has spread to other parts of the body (metastatic). Ogivri works by targeting and blocking HER2, a protein that promotes cancer cell growth, helping to slow or stop tumor progression.

Heart
Medication Guide Icon Medication Guide
Patient Website Icon Patient Website
Efficacy Data Icon Efficacy Data
New Articles Icon New Articles
Savings and Support Icon Savings and Support
Company MD Payments Icon Company MD Payments
Clinical Trials Icon Clinical Trials
Adverse Event Report Icon Adverse Event Report
Other top medicines used to treat Gastric Cancer - Stomach Cancer